Allergan Seeking Buyers for Women's Health and Infectious Disease Assets; Shares Still Undervalued
Allergan has announced that it will attempt to sell its women's health and infectious disease segments as part of the company's recent strategic review. Combined sales for these assets currently represent about 6% of revenue. We're not particularly surprised by the announcement given Allergan's lack of leadership in these categories and greater ease to separate them from the rest of the business. Additionally, recent restrictions on uterine fibroid drug Esmya in Europe over liver concerns dimini...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.